A Biological Evaluation Of Some 2′-Substituted Analogs Of MPTP

  • Stephen K. Younster
  • Richard E. Heikkila


1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been shown to produce a Parkinsonian syndrome in man (Davis et al., 1979; Langston et al., 1983) and to destroy the nigrostriatal dopaminergic pathway in monkeys (Burns et al., 1983; Langston et al., 1984a) and mice (Heikkila et al., 1984a; Hallman et al., 1985). The discovery that administration of such a simple chemical substance can reproduce the behavioral and pathological symptoms of Parkinson’s disease has led some investigators to suggest that idiopathic Parkinson’s disease may be caused by a compound present either in the environment or as an endogenous biological constituent (Snyder and D’Amato, 1986). Searches have been conducted for compounds structurally similar to MPTP which might be responsible for producing idiopathic Parkinson’s disease and thousands of compounds, either synthesized in the laboratory or isolated from natural sources, have been identified which share certain structural features with MPTP (Markey and Schmuff, 1986). Our laboratory has been involved in the synthesis and evaluation of the neurotoxic potential of numerous analogs of MPTP with the intent of defining the structural requirements for production of MPTP-like neurotoxicity so that we will be able to predict the likelihood that any particular compound will be an MPTP-like neurotoxin.


Dopaminergic Neuron Parkinsonian Syndrome Nigrostriatal Dopamine Neurotoxic Potential Dopaminergic Neurotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burns, R.S., C.C. Chiueh, S.P. Markey, M.H Ebert, D.M. Jacobowitz and I.J. Kopin, 1983, A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci., U.S.A. 80:4546–4550.PubMedCrossRefGoogle Scholar
  2. Bradbury, A.J., Costall, B., Domeney, A.M., Jenner, P., Kelly, M.E., Marsden, C.D, andNaylor, R.J., 1986, MPP + is neurotoxic to the nigrostriatal dopamine pathway, Nature 319:56–7PubMedCrossRefGoogle Scholar
  3. Chiba, K., Petersen, K.P., Castagnoli, K.P., Trevor, A.J., and Castagnoli, N. Jr., 1985, Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine, Drug Metab. Disp. 13:342–347Google Scholar
  4. Chiba, K. A., Trevor, A.J., and Castagnoi, N. Jr., 1984, Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase, Biochem. Biophys. Res. Commun. 120:674–578.CrossRefGoogle Scholar
  5. David, G.C., Williams, A.C., Markey., S.P., Ebert, M.H., Caine, E.D, Reichert, C.M., and Kopin, I.J, 1979, Chronic parkinsonism secondary to intravenous injection of meperidine analogues, Psychiatry Res. 1:249–254.CrossRefGoogle Scholar
  6. Fries, D.S, Vries, J.D., Hazelhoff, B., and Horn, A.S., 1986, Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues, J. Med. Chem. 29:424–427.PubMedCrossRefGoogle Scholar
  7. Gessner, W., Brossi, A., Shen, R., and Abell, C.W., 1985, Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl/1,2,3,6-tetrahydropyridine (MPTP), FEBS Lett. 183:345–348.PubMedCrossRefGoogle Scholar
  8. Hallman, H., Lange, J., Olson, L., Stromberg, I. and Jonsson, G. 1985, Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catechalamine neurons in the mouse, J. Neurochem. 44:117–127.PubMedCrossRefGoogle Scholar
  9. Heikkila, R.E., Hess, A., and Duvoisin, R.C., 1984a, Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice, Science, 224: 1451–1453.PubMedCrossRefGoogle Scholar
  10. Heikkila, R.E., Kindt, M.V. Sonsalla, P.K. Giovanni, A., Youngster S.K., McKeown, K.A. and Singer, T.P. in press, Proc. Natl. Acad. Sci., U.S.A.Google Scholar
  11. Heikkila, R.E., Manzino, L., Cabbat, F.S., and Duvoisin, R.C., 1984b, Protection against the dopaminergic neurotoxicity of 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors, Nature 311:467–469CrossRefGoogle Scholar
  12. Heikkila, R.E., Nicklas, W.J., and Duvoisin, R.C., 1985, Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP +) to rats, Neurosci. Lett. 59:135–140.PubMedCrossRefGoogle Scholar
  13. Javitch, J.A., D’Amato, R.J, Strittmatter, S.M., and Snyder, S.H.1985, Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopaine neurons explains selective toxicity, Proc. Natl. Acad. Sci., U.S.A. 82:2173–2177.PubMedCrossRefGoogle Scholar
  14. Kindt, M.V., Heikkila, R.E., and Nicklas, W.J., 1987, Mitochondrial and metabolic toxicity of l-metyl-4-(2′methylphenyl)-1,2,3,6-tetrahydropyridine, J. Pharmacol. Exp. Ther. 242:858–863.PubMedGoogle Scholar
  15. Kindt, M.V. Youngster, S.K. Sonsalla, P.K., Duvoisin, R.C., and Heikkila, R.E., in press Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2′Me-MPTP, Eur. J. Pharmacol.Google Scholar
  16. Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. 1983, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219:979–980.PubMedCrossRefGoogle Scholar
  17. Langston, J.W., Forao, L.S., Rebert, C.S., and Irwin, I., 1984a, Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey, Brain Res. 292:390–394.PubMedCrossRefGoogle Scholar
  18. Langston, J.W., Irwin, I., Langston, E.B., and Forno, L.S., 1984b, Pargylineprevents MPTP-inducedparkinsonism in primates, Science 225:1480–1482.PubMedCrossRefGoogle Scholar
  19. Lewin R., 1985, Clinical trials for Parkinson’s disease? Science 230:527.PubMedCrossRefGoogle Scholar
  20. Markey, S.P., Johannessen, J.N., Chiueh, C.C., Burns, R.S., and Herkenham, M.A., 1984, Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism, Nature 311:464–467.PubMedCrossRefGoogle Scholar
  21. Markey, S.P. and Schmuff, N.R., 1986, The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds, Med. Res. Rev. 6:386–429.CrossRefGoogle Scholar
  22. Mayer, R.A., Kindt, M.V., and Heikkila, R.E., 1986, Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport, J. Neurochem, 47:1073–1079.PubMedCrossRefGoogle Scholar
  23. Mytilineou, C., Cohen, G., and Heikkila, R.E., 1985, 1-methyl-4-phenylpyridine (MPP +) is toxic to mesencephalic dopamine neurons in culture, Neurosci. Lett. 57:19–24PubMedCrossRefGoogle Scholar
  24. Nicklas, W.J. Vyas, I., and Heikkila, R.E., 1985, Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahyd-ropyridine, Life Sci. 36, 2503–2508.PubMedCrossRefGoogle Scholar
  25. Nicklas, W.J., Younster, S.K., Kindt, M.V., and Heikkila, R.E., 1986, MPTP, MPP+, and mitochondrial function, Life Sci 40:721–729.CrossRefGoogle Scholar
  26. Ramsay, R.R., Salach, J.I., Dadgar, J. and Singer, T.P. 1986, Inhibition of mitrochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism, Biochem. Biophys. Res. Commun. 135:743–748.CrossRefGoogle Scholar
  27. Snyder, S.H. and D’ Amato, 1986, MPTP, a neurotoxin relevant to the pathophysiology of Parkinson’s disease, Neurology 36:250–258.PubMedGoogle Scholar
  28. Sonsalla, P.K., Youngster, S.K., Kindt, M.V., and Heikkila, R.E., 1987, Characteristics of 1-methyl-4-(2′-methylphenyl)-l,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse, J. Pharmacol. Exp. Ther. 242:850–857.PubMedGoogle Scholar
  29. Vyas, I., Heikkilla, R.E., and Nicklas, W.J., 1986, Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenyl-pyridinium, J. Neurochem. 46:1501–1507.PubMedCrossRefGoogle Scholar
  30. Youngster, S.K., Duvoisin, R.C., Hess, A., Sonsalla, P.K., Kindt, M.V., andHeikikila, R.E., 1986,1-Methyl-4-(2′-methyphenyl)-l,2,3,6-tetrahydropyridine (2′Me-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice, Eur. J. Pharmacol. 122:283–287.PubMedCrossRefGoogle Scholar
  31. Youngster, S.K., Sonsalla, P.K., and Heikkila, R.E., 1987, Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin MPTP, J. Neurochem. 48:929–934PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Stephen K. Younster
    • 1
  • Richard E. Heikkila
    • 1
  1. 1.Department of NeurologyUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolPiscatawayUSA

Personalised recommendations